Current clinical applications in tissue engineering and cell therapy

Approaches to the use of tissue engineering and cell therapies are varied, but all capitalize on the inherent healing abilities that can be leveraged in normal cell and tissue repair and development.  The clinical applications have also proliferated, not simply in terms of the potential patient caseload, but in the actual patient populations for which treatments are in trial if not in current, approved use.

When we previously provided a global analysis of tissue engineering and cell therapy markets (2005), our perspective on the near- and mid-term market prospects was to mitigate the wildly optimistic views that pervaded forecasts:

The excitement around tissue engineering and regenerative medicine is pervasive, with items in the news on at least a weekly basis announcing a potential cure for Parkinson’s or the regrowing of a thumb or the implantation of a liver from a genetically-modified pig. Tissue engineering and cell therapy is a young industry that will assuredly change the face of medicine, but not quite as rapidly as some forecasts suggest. 

However, our research has shown a burst in development and clinical success that is frankly supportive of optimistic forecasts. The successes have come in terms of eased regulation for cell therapies, aggressive development of non-embryonic stem cell therapies (due to prior restrictions on embryonic) and big advances in the application of cell/tissue technologies in more acute conditions like myocardial infarction.

Below are the range of clinical applications, with current or near-term potential caseload, for cell therapy and tissue engineering:

  • Coronary Heart Disease
    • Myocardial Infarction
    • Congestive Heart Failure
    • Dysfunctional Heart Valves
    • Peripheral Vascular Disorders
    • Abdominal Aortic Aneurysms
  • Neurological
    • Stroke
    • Parkinson’s Disease
    • Alzheimer’s Disease
    • Epilepsy
    • Traumatic Brain and Spinal Cord Injury
    • Multiple Sclerosis
  • Orthopedic
    • Non-union Fractures
    • Cartilage Damage and Repair
    • Ligament Damage
    • Vertebral Disc Damage
    • Bone Graft Materials
  • Urological
    • Incontinence
    • Kidney Disease
    • Bladder
  • Skin/Integumentary
    • Burns
    • Diabetic Ulcers
    • Venous Ulcers
    • Plastic Surgery
  • Dental
    • Missing teeth
    • Periodontal disease
  • Organ Transplantation
    • Liver
    • Heart
    • Kidney
    • Pancreas
  • Ophthalmology
    • Cornea
    • Retina
  • Gastrointestinal
    • Esophagus
    • Stomach
    • Small Intestine
    • Colon
  • Ear, Nose and Throat/Respiratory/Cardiopulmonary
    • Trachea
    • Respiratory Epithelial Cells (Nasal Turbinates)
  • Cancer
    • Urology (Bladder, kidney/Renal cell, prostate)
    • Neurology (Brain/Glioblastoma/Glioma, CNS, head/Neck)
    • Obstetrics/Gynecology (Breast, pelvic, ovarian, endometrial)
    • Orthopedic (Chordoma/Bone)
    • Gastrointestinal/Gastroenterology (Colorectal, gastric, pancreas)
    • ENT (Esophageal, oral, pharynx, olfactory)
    • Hematopoietic (Leukemia, lymphoma)
    • Respiratory (Lung/Mesothelioma)
    • Dermatology (Melanoma/Skin)

See Report #S520, "Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, Worldwide, 2009-2018", publishing January 2010.

4 thoughts on “Current clinical applications in tissue engineering and cell therapy”

  1. yeah sure thing, in particular nerve tissue engineering is more like a science fiction than the accurate science. this report is way too optimistic.

  2. How are you determining that the report is "way too optimistic" (especially since we have no record that you have access to the report)? We have tracked **actual manufacturer revenues** in this industry for 10+ years. Our forecasts consider what sales have already happened (and reported on by publicly-traded companies), trends in sales growth, and the anticipated introduction of new products in the short term. We have found this to result in a respectably low margin of error when comparing forecast to observed after the fact.

  3. I was wondering if you are able to point out which of the the procedures you have listed are current and which are potential.
    Thanks : )

  4. The applications that are current, and the associated revenues, are part of the report we published (#S520), so you would have to gain access to the report to have those details.

Leave a Reply